Increased R&D spending in 2016, including the development of clinical trials for RECORLEV for the treatment of endogenous Cushing's syndrome by Strongbrigde Biopharma plc, is likely to increase competition and favour the growth of multiple manufacturers competing to lead the market. Corcept Therapeutics is a significant participant in the Cushing's syndrome industry. Cushing's syndrome is classified geographically as follows: North America, Europe, Asia-Pacific, the Middle East, Latin America, and Africa. Because of the high economic standard and health awareness in North America, the market for Cushing's syndrome is expected to rise.
Key Companies in the Cushing’s syndrome Industry:
1. Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
2. HRA Pharma
HRA Pharma, SA develops and commercializes drugs, devices, and services in the therapeutic areas of reproductive health and endocrine diseases. The company distributes and markets its products directly in the European Union, including France, Germany, and the United Kingdom, as well as through license agreements in France and internationally. HRA Pharma, SA was founded in 1996 and is based in Paris, France. It has subsidiary locations in Bochum, Germany; London, the United Kingdom; and New York, New York.
3. Strongbridge Biopharma plc.
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Founded in 1996, headquartered in Dublin, Ireland.
4. Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
*Definition- Cushing's syndrome is characterised by high blood pressure, crimson stretch marks, abdominal obesity, a round red face, weak muscles, weak bones, a fat mass between the shoulders, and fragile skin that heals slowly owing to extended cortisol exposure. The two main causes of Cushing's syndrome are excessive cortisol-like medicines such as prednisone and tumours generated by adrenal glands owing to excess cortisol.
